Our research team assigns Bronze ratings to strategies they’re ... but added Regeneron Pharmaceuticals REGN in 2020 and then Vertex Pharmaceuticals VRTX in 2022. The fund also added ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Process, and Parent Pillars, suggests that this share class can deliver positive alpha against its category benchmark, leading to its Morningstar Medalist Rating of Bronze.

The lawsuit against Ana Knezevich's estranged husband David includes claims for wrongful death, fraudulent transfers and ...

In Project Bronze Forever, your goal is to collect as many Pokemon as possible to fill up your Pokedex. You also can earn money to purchase valuable items to help heal, level up, and revive your ...

Keep up with the markets, earnings, and economy with high-quality news from 1,000s of journalists around the world.

* Anand M - Editor & Mentor: Anand is an avid investor and has nearly 28 years experience in Indian Stock Markets. He is currently the mentor, IT head and Editor. * Venkatesh - Founder: Venkatesh ...